jes-pa-bypass-confirmatory

Identifies patients with a positive aldosterone-to-renin ratio screening who may proceed directly to subtype testing without confirmatory testing based on specific clinical criteria. Triggers include

SKILL.md

GitHub

Determine when confirmatory testing can be bypassed for PA diagnosis

STEP 1 — Gather Information

Collect screening results: aldosterone-to-renin ratio (ARR) ≥200 (PAC/PRA) or ≥40 (PAC/ARC) with PAC ≥60 pg/mL (CLEIA); note spontaneous hypokalemia (serum K+ <3.5 mEq/L), baseline PAC >100 pg/mL (CLEIA), and renin suppression (PRA <0.5 ng/mL/h or ARC <2.5 pg/mL).

STEP 2 — Rule In / Rule Out

If the patient has a positive screening test AND exhibits spontaneous hypokalemia, baseline PAC >100 pg/mL (CLEIA), and renin suppression, rule in for bypassing confirmatory test; otherwise, rule out bypass and proceed to confirmatory testing.

STEP 3 — Classify or Stratify

Classify as eligible for confirmatory test bypass when all three criteria (spontaneous hypokalemia, high baseline PAC, renin suppression) are present; stratify as not eligible if any criterion is missing.

STEP 4 — Decide

Decide to skip confirmatory testing and move directly to subtype testing (e.g., adrenal venous sampling) for patients meeting all bypass criteria; for those not meeting criteria, order a confirmatory test (e.g., captopril challenge test or saline infusion test).

Clinical Guardrails / Mimics / Pitfalls

Do not bypass confirmatory testing in patients with borderline PAC (60–100 pg/mL CLEIA), normokalemia, or incomplete renin suppression; avoid mistaking diuretic-induced hypokalemia for spontaneous hypokalemia; remember that bypass does not exclude the need for subtype testing before adrenalectomy.

Concrete Clinical Example

A 45-year-old hypertensive patient presents with spontaneous hypokalemia (K+ 3.0 mEq/L), screening ARR 250 (PAC/PRA) with PAC 120 pg/mL (CLEIA), and PRA 0.2 ng/mL/h. All bypass criteria are met, so confirmatory testing is skipped and adrenal venous sampling is performed for subtype classification.

Source: Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021, Japan Endocrine Society, 2021